Quick Answer
Co-Diagnostics, Inc. reported Total Revenue of $622.5 thousand for fiscal year 2025.
Co-Diagnostics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $622.5K -84.1% |
$3.92M -42.5% |
$6.81M -80.1% |
$34.22M -65.0% |
$97.89M +31.3% |
$74.55M +34579.9% |
| Revenue (ASC 606) | $622.5K -84.1% |
$3.92M -42.5% |
$6.81M -80.1% |
$34.22M -65.0% |
$97.89M +31.3% |
$74.55M +34579.9% |
| Net Income | -$46.90M -24.6% |
-$37.64M -6.5% |
-$35.33M -148.2% |
-$14.24M -138.8% |
$36.66M -13.7% |
$42.48M +785.6% |
| Diluted EPS | -$35.25 +5.3% |
-$37.22 -3001.7% |
-$1.20 -166.7% |
-$0.45 -136.6% |
$1.23 -19.1% |
$1.52 +510.8% |
| Total Assets | $24.74M -61.1% |
$63.56M -33.3% |
$95.32M -22.6% |
$123.09M -23.1% |
$160.03M +124.6% |
$71.24M +3115.7% |
| Cash and Equivalents | $11.88M +304.7% |
$2.94M -80.3% |
$14.92M -35.1% |
$22.97M -74.1% |
$88.61M +106.2% |
$42.98M +4711.9% |
| Stockholders Equity | $20.63M -61.7% |
$53.88M -37.0% |
$85.58M -25.3% |
$114.52M -14.8% |
$134.48M +101.6% |
$66.70M +3739.2% |
| R&D Expense | $19.14M -8.8% |
$20.98M -8.6% |
$22.96M +31.7% |
$17.44M +16.5% |
$14.96M +369.7% |
$3.19M +132.3% |
| Operating Income | -$50.17M -25.2% |
-$40.08M +6.1% |
-$42.71M -58.3% |
-$26.98M -158.6% |
$46.06M +10.5% |
$41.69M +807.4% |
| Gross Profit | $400.1K -86.3% |
$2.92M +11.0% |
$2.63M -90.9% |
$28.74M -66.7% |
$86.31M +48.9% |
$57.96M +56424.0% |
| Shares Outstanding | 30 -100.0% |
1.10M -96.5% |
31.26M +1.3% |
30.87M -8.7% |
33.82M +18.4% |
28.56M +64.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $145.4K | -77.3% | -10.8% |
| Revenue (ASC 606) | September 30, 2025 | $145.4K | -77.3% | -10.8% |
| Net Income | September 30, 2025 | -$5.89M | +39.3% | +23.8% |
| Diluted EPS | September 30, 2025 | -$0.16 | +50.0% | +30.4% |
| Total Assets | September 30, 2025 | $44.74M | -38.2% | -3.7% |
| Cash and Equivalents | September 30, 2025 | $11.44M | +6.0% | +3.0% |
| Stockholders Equity | September 30, 2025 | $39.83M | -37.6% | -3.2% |
| R&D Expense | September 30, 2025 | $4.48M | -8.2% | -4.4% |
| Operating Income | September 30, 2025 | -$7.01M | +31.5% | +13.0% |
| Gross Profit | September 30, 2025 | $119.1K | -65.4% | -9.0% |
| Shares Outstanding | September 30, 2025 | 48.14M | +50.8% | +33.1% |
- Co-Diagnostics, Inc. reported Total Revenue of $622.5 thousand for fiscal year 2025.
- Co-Diagnostics, Inc. showed a decrease of -84.1% in Total Revenue compared to the prior fiscal year.
- Co-Diagnostics, Inc. reported Revenue (ASC 606) of $622.5 thousand for fiscal year 2025.
- Co-Diagnostics, Inc. showed a decrease of -84.1% in Revenue (ASC 606) compared to the prior fiscal year.
- Co-Diagnostics, Inc. reported Net Income of -$46.90 million for fiscal year 2025.
- Co-Diagnostics, Inc. showed a decrease of -24.6% in Net Income compared to the prior fiscal year.
- Co-Diagnostics, Inc. reported Diluted EPS of $35.25 per share (loss) for fiscal year 2025.
- Co-Diagnostics, Inc. showed an increase of +5.3% in Diluted EPS compared to the prior fiscal year.
- Co-Diagnostics, Inc. reported Total Assets of $24.74 million for fiscal year 2025.
- Co-Diagnostics, Inc. showed a decrease of -61.1% in Total Assets compared to the prior fiscal year.
- Co-Diagnostics, Inc. reported Cash and Equivalents of $11.88 million for fiscal year 2025.
- Co-Diagnostics, Inc. showed an increase of +304.7% in Cash and Equivalents compared to the prior fiscal year.
- Co-Diagnostics, Inc. reported Stockholders Equity of $20.63 million for fiscal year 2025.
- Co-Diagnostics, Inc. showed a decrease of -61.7% in Stockholders Equity compared to the prior fiscal year.
- Co-Diagnostics, Inc. reported R&D Expense of $19.14 million for fiscal year 2025.
- Co-Diagnostics, Inc. showed a decrease of -8.8% in R&D Expense compared to the prior fiscal year.
- Co-Diagnostics, Inc. reported Operating Income of -$50.17 million for fiscal year 2025.
- Co-Diagnostics, Inc. showed a decrease of -25.2% in Operating Income compared to the prior fiscal year.
- Co-Diagnostics, Inc. reported Gross Profit of $400.1 thousand for fiscal year 2025.
- Co-Diagnostics, Inc. showed a decrease of -86.3% in Gross Profit compared to the prior fiscal year.
- Co-Diagnostics, Inc. reported Shares Outstanding of 2.10 million shares for fiscal year 2025.
- Co-Diagnostics, Inc. showed an increase of +6983336.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: